0OG Stock Chart & Stats
€0.80
<€0.01(0.63%)
At close: 4:00 PM EDT
€0.80
<€0.01(0.63%)
Day’s Range― - ―
52-Week Range€0.74 - €1.82
Previous CloseN/A
Volume0.00
Average Volume (3M)224.00
Market Cap
€121.42M
Enterprise Value€217.07
Total Cash (Recent Filing)€54.75M
Total Debt (Recent Filing)€8.20M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Dec 22, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding136,468,690
10 Day Avg. Volume521
30 Day Avg. Volume224
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)1.03
Price to Sales (P/S)1.39
P/FCF Ratio-14.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.94Price Target Upside143.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.07
Revenue Forecast (FY)€209.35M
Bulls Say, Bears Say
Bulls Say
Acquisition And European ExpansionAnalyst considers the acquisition strategically significant as it positions Organigram in Germany and creates a platform to expand across European markets, supporting potential revenue growth.
Higher-margin Product SalesAnalyst notes the deal enables Organigram to sell higher-margin flower into European markets, which could improve overall profitability as international sales scale.
Operational Strength And DistributionAnalyst points to Sanity Group's improving gross margins and positive operating profitability, together with the Motif acquisition's added sales channels, as elements that can strengthen margins and accelerate top-line growth.
Bears Say
Balance Sheet Impact And Shareholder DilutionAnalyst warns the transaction requires cash and issuance of Organigram shares, which could weaken the balance sheet and alter shareholder structure through dilution.
Operational Disruption And Product Quality RiskAnalyst highlights operational disruptions and product quality issues that constrained international shipments and increased competitive pressure in certain categories, posing execution risk.
Revenue And Earnings ShortfallAnalyst reports net revenue missed expectations because international sales were weaker and domestic adult-use demand softened, resulting in adjusted operating earnings falling short of forecasts.
0OG FAQ
What was Organigram Global’s price range in the past 12 months?
Organigram Global lowest stock price was €0.74 and its highest was €1.82 in the past 12 months.
What is Organigram Global’s market cap?
Organigram Global’s market cap is €121.42M.
When is Organigram Global’s upcoming earnings report date?
Organigram Global’s upcoming earnings report date is Dec 22, 2026 which is in 131 days.
How were Organigram Global’s earnings last quarter?
Organigram Global released its earnings results on Aug 11, 2026. The company reported €0.473 earnings per share for the quarter, beating the consensus estimate of -€0.006 by €0.479.
Is Organigram Global overvalued?
According to Wall Street analysts Organigram Global’s price is currently Undervalued.
Does Organigram Global pay dividends?
Organigram Global does not currently pay dividends.
What is Organigram Global’s EPS estimate?
Organigram Global’s EPS estimate is 0.01.
How many shares outstanding does Organigram Global have?
Organigram Global has 136,468,690 shares outstanding.
What happened to Organigram Global’s price movement after its last earnings report?
Organigram Global reported an EPS of €0.473 in its last earnings report, beating expectations of -€0.006. Following the earnings report the stock price went up 4.798%.
Which hedge fund is a major shareholder of Organigram Global?
Currently, no hedge funds are holding shares in DE:0OG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Organigram Global Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€1.94 (143.05% Upside)
€1.94 (143.05% Upside)
Blogger Sentiment
Bullish
DE:0OG Sentiment 67%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €23.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
39.72%
Trailing 12-Months
Company Description
Organigram Global
Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O’ Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings and dried flowers to other licensed producers. It sells cannabis products to wholesale and retail channels in the recreational and medical cannabis regimes, as well as through online. Organigram Global Inc. was formerly known as Organigram Holdings Inc. and changed its name to Organigram Global Inc. in March 2025. The company is headquartered in Toronto, Canada.
0OG Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational and financial momentum driven largely by the Sanity acquisition: record revenue, margin expansion, record adjusted EBITDA, and meaningful international diversification. Operational improvements in cultivation and category share gains in Canada reinforce the positive narrative. Key risks include negative free cash flow driven by working capital build, pending EU-GMP certification and tight EU-GMP supply into Germany, earlier vape/pre-roll quality issues in Canada, and U.S. regulatory uncertainty. Net income was materially boosted by non-cash fair value gains, so underlying cash generation and integration-related working capital remain focal concerns. On balance, the positive financial results, strategic diversification, and improving margin trajectory outweigh the liquidity and regulatory challenges discussed.View all DE:0OG earnings summaries0OG Stock 12 Month Forecast
Average Price Target
€1.94
▲(143.05% Upside)
Technical Analysis
Canopy Growth
―
Aurora Cannabis
―
Cronos Group
―
Curaleaf Holdings
―
Green Thumb Industries
―











